Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines

Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) vaccines. ChAdOx1 nC...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalik, Stephan, Siegerist, Florian, Palankar, Raghavendra, Franzke, Kati, Schindler, Maximilian, Reder, Alexander, Seifert, Ulrike, Cammann, Clemens, Wesche, Jan, Steil, Leif, Hentschker, Christian, Gesell-Salazar, Manuela, Reisinger, Emil, Beer, Martin, Endlich, Nicole, Greinacher, Andreas, Völker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968905/
https://www.ncbi.nlm.nih.gov/pubmed/35045692
http://dx.doi.org/10.3324/haematol.2021.280154
_version_ 1784679144336916480
author Michalik, Stephan
Siegerist, Florian
Palankar, Raghavendra
Franzke, Kati
Schindler, Maximilian
Reder, Alexander
Seifert, Ulrike
Cammann, Clemens
Wesche, Jan
Steil, Leif
Hentschker, Christian
Gesell-Salazar, Manuela
Reisinger, Emil
Beer, Martin
Endlich, Nicole
Greinacher, Andreas
Völker, Uwe
author_facet Michalik, Stephan
Siegerist, Florian
Palankar, Raghavendra
Franzke, Kati
Schindler, Maximilian
Reder, Alexander
Seifert, Ulrike
Cammann, Clemens
Wesche, Jan
Steil, Leif
Hentschker, Christian
Gesell-Salazar, Manuela
Reisinger, Emil
Beer, Martin
Endlich, Nicole
Greinacher, Andreas
Völker, Uwe
author_sort Michalik, Stephan
collection PubMed
description Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S.
format Online
Article
Text
id pubmed-8968905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-89689052022-04-11 Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines Michalik, Stephan Siegerist, Florian Palankar, Raghavendra Franzke, Kati Schindler, Maximilian Reder, Alexander Seifert, Ulrike Cammann, Clemens Wesche, Jan Steil, Leif Hentschker, Christian Gesell-Salazar, Manuela Reisinger, Emil Beer, Martin Endlich, Nicole Greinacher, Andreas Völker, Uwe Haematologica Article Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S. Fondazione Ferrata Storti 2022-01-20 /pmc/articles/PMC8968905/ /pubmed/35045692 http://dx.doi.org/10.3324/haematol.2021.280154 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Michalik, Stephan
Siegerist, Florian
Palankar, Raghavendra
Franzke, Kati
Schindler, Maximilian
Reder, Alexander
Seifert, Ulrike
Cammann, Clemens
Wesche, Jan
Steil, Leif
Hentschker, Christian
Gesell-Salazar, Manuela
Reisinger, Emil
Beer, Martin
Endlich, Nicole
Greinacher, Andreas
Völker, Uwe
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title_full Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title_fullStr Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title_full_unstemmed Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title_short Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
title_sort comparative analysis of chadox1 ncov-19 and ad26.cov2.s sars-cov-2 vector vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968905/
https://www.ncbi.nlm.nih.gov/pubmed/35045692
http://dx.doi.org/10.3324/haematol.2021.280154
work_keys_str_mv AT michalikstephan comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT siegeristflorian comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT palankarraghavendra comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT franzkekati comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT schindlermaximilian comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT rederalexander comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT seifertulrike comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT cammannclemens comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT weschejan comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT steilleif comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT hentschkerchristian comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT gesellsalazarmanuela comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT reisingeremil comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT beermartin comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT endlichnicole comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT greinacherandreas comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines
AT volkeruwe comparativeanalysisofchadox1ncov19andad26cov2ssarscov2vectorvaccines

Ejemplares similares